Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

INHIBITION BY SERUM OF AUTOIMMUNE ASPERMATOGENIC ORCHITIS.

Autor: Bernard, CC, Toullet, Francine, Lamoureux, G

Publikováno v: Immunology & Cell Biology; Jun1975, Vol. 53 Issue 3, p245-250, 6p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis.

Autor: Pouzol L; Drs. Pouzol and Clozel were with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and are presently with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland.; Dr. Piali was with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and is presently with Hoffmann la Roche in Basel, Switzerland.; Dr. Bernard is with Monash University, Faculty of Medicine, Nursing & Health Sciences in Melbourne, Australia.; Dr. Martinic is with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland.; Dr. Steiner was with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research., Piali L; Drs. Pouzol and Clozel were with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and are presently with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland.; Dr. Piali was with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and is presently with Hoffmann la Roche in Basel, Switzerland.; Dr. Bernard is with Monash University, Faculty of Medicine, Nursing & Health Sciences in Melbourne, Australia.; Dr. Martinic is with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland.; Dr. Steiner was with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research., Bernard CC; Drs. Pouzol and Clozel were with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and are presently with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland.; Dr. Piali was with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and is presently with Hoffmann la Roche in Basel, Switzerland.; Dr. Bernard is with Monash University, Faculty of Medicine, Nursing & Health Sciences in Melbourne, Australia.; Dr. Martinic is with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland.; Dr. Steiner was with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research., Martinic MM; Drs. Pouzol and Clozel were with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and are presently with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland.; Dr. Piali was with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and is presently with Hoffmann la Roche in Basel, Switzerland.; Dr. Bernard is with Monash University, Faculty of Medicine, Nursing & Health Sciences in Melbourne, Australia.; Dr. Martinic is with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland.; Dr. Steiner was with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research., Steiner B; Drs. Pouzol and Clozel were with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and are presently with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland.; Dr. Piali was with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and is presently with Hoffmann la Roche in Basel, Switzerland.; Dr. Bernard is with Monash University, Faculty of Medicine, Nursing & Health Sciences in Melbourne, Australia.; Dr. Martinic is with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland.; Dr. Steiner was with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research., Clozel M; Drs. Pouzol and Clozel were with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and are presently with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland.; Dr. Piali was with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and is presently with Hoffmann la Roche in Basel, Switzerland.; Dr. Bernard is with Monash University, Faculty of Medicine, Nursing & Health Sciences in Melbourne, Australia.; Dr. Martinic is with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland.; Dr. Steiner was with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research.

Publikováno v: Innovations in clinical neuroscience [Innov Clin Neurosci] 2019 Mar 01; Vol. 16 (3-4), pp. 22-30.